- Home
- XPEL vs XERS Comparison
XPEL vs XERS Comparison
Compare XPEL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEL
- XERS
- Stock Information
- Founded
- XPEL 1999
- XERS 2005
- Country
- XPEL United States
- XERS United States
- Employees
- XPEL N/A
- XERS N/A
- Industry
- XPEL Industrial Specialties
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- XPEL Industrials
- XERS Health Care
- Exchange
- XPEL Nasdaq
- XERS Nasdaq
- Market Cap
- XPEL 1.2B
- XERS 1.3B
- IPO Year
- XPEL N/A
- XERS 2018
- Fundamental
- Price
- XPEL $44.19
- XERS $6.85
- Analyst Decision
- XPEL
- XERS Strong Buy
- Analyst Count
- XPEL 0
- XERS 7
- Target Price
- XPEL N/A
- XERS $10.00
- AVG Volume (30 Days)
- XPEL 375.1K
- XERS 2.9M
- Earning Date
- XPEL 11-05-2025
- XERS 11-06-2025
- Dividend Yield
- XPEL N/A
- XERS N/A
- EPS Growth
- XPEL N/A
- XERS N/A
- EPS
- XPEL 1.69
- XERS N/A
- Revenue
- XPEL $461,460,000.00
- XERS $266,137,000.00
- Revenue This Year
- XPEL $12.54
- XERS $43.89
- Revenue Next Year
- XPEL $10.52
- XERS $20.40
- P/E Ratio
- XPEL $26.17
- XERS N/A
- Revenue Growth
- XPEL 10.29
- XERS 42.05
- 52 Week Low
- XPEL $24.25
- XERS $3.02
- 52 Week High
- XPEL $47.23
- XERS $10.08
- Technical
- Relative Strength Index (RSI)
- XPEL 77.86
- XERS 29.56
- Support Level
- XPEL $39.61
- XERS $7.00
- Resistance Level
- XPEL $41.20
- XERS $7.27
- Average True Range (ATR)
- XPEL 1.95
- XERS 0.53
- MACD
- XPEL 0.54
- XERS -0.19
- Stochastic Oscillator
- XPEL 94.67
- XERS 4.01
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).